Development
Cytokinetics, Incorporated
CYTK
$36.16
-$0.42-1.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -0.76% | -87.24% | -84.49% | -83.00% | -89.23% |
| Total Other Revenue | -- | -100.00% | -100.00% | -- | -- |
| Total Revenue | -92.04% | -94.73% | -93.42% | 50.79% | 34.30% |
| Cost of Revenue | 37.09% | 52.97% | 54.04% | 57.36% | 50.57% |
| Gross Profit | -120.61% | -411.53% | -562.41% | -61.27% | -63.36% |
| SG&A Expenses | -2.45% | 16.26% | 41.08% | 70.27% | 83.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.28% | 37.19% | 48.72% | 62.47% | 63.12% |
| Operating Income | -53.05% | -126.53% | -168.32% | -65.87% | -74.01% |
| Income Before Tax | -35.30% | -86.69% | -149.91% | -67.20% | -80.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.30% | -86.69% | -149.91% | -67.20% | -80.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.30% | -86.69% | -149.91% | -67.20% | -80.65% |
| EBIT | -53.05% | -126.53% | -168.32% | -65.87% | -74.01% |
| EBITDA | -52.11% | -128.33% | -170.49% | -65.32% | -73.00% |
| EPS Basic | -28.21% | -74.45% | -119.40% | -42.18% | -50.25% |
| Normalized Basic EPS | -36.87% | -90.65% | -112.86% | -36.16% | -40.75% |
| EPS Diluted | -28.21% | -74.40% | -119.08% | -42.02% | -50.05% |
| Normalized Diluted EPS | -36.87% | -90.65% | -112.86% | -36.16% | -40.75% |
| Average Basic Shares Outstanding | 7.49% | 9.50% | 13.19% | 15.00% | 16.85% |
| Average Diluted Shares Outstanding | 7.49% | 9.50% | 13.19% | 15.00% | 16.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |